We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > Noxopharm

News List

Noxopharm’s Veyonda prevents cytokine storm in Covid-19 trial pharmaceutical-technology
April 26, 2021
Australian company Noxopharm has reported interim data from its NOXCOVID trial, which showed that its drug candidate Veyonda provided protection against hyper-inflammation (cytokine storm) in moderate Covid-19 patients.
Noxopharm Files Septic Shock Treatment Patent for Veyonda® americanpharmaceuticalreview
April 15, 2021
Australian clinical-stage drug development company Noxopharm Limited announced an international patent application aimed at protecting the use of experimental anti-cancer drug, Veyonda® (idronoxil), in blocking the development of septic shock ...
Noxopharm reports Covid-19 trial programme to commence in Europe pharmaceutical-business-review
July 01, 2020
Noxopharm, a clinical-stage Australian drug development company, has announced commencement of its NOXCOVID clinical program with a planned Phase I trial in Europe.